STAAR Surgical's revenue growth was driven entirely by 19% growth (20% at constant currency) in sales of its Implantable Collamer Lens (ICL) products to $93.1 million, offset partially by a $0.7 ...

--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ ... driven by the continuing expansive growth of our EVO Visian ICL™ family of lenses,” said Caren Mason, President and CEO.

Tom Stephan, Stifel: Asked about ICL sellout trends in China for Q1 ... s long-term optimism despite short-term challenges. STAAR Surgical is addressing immediate challenges, including inventory ...

About STAAR Surgical STAAR, which has been dedicated ... in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes the EVO Visian ICL™ product line.

March 18, 2024--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia ...

STAAR Surgical attributed the weak performance to deteriorating demand in China, its largest market. ICL (TASE:ICL) sales in China dropped to just $7.5 million in Q4, dragging down overall ICL ...

Staar Surgical reported a Q4 2024 EPS loss of 69 cents, missing the consensus, with revenue dropping 36% to $48.9 million. The company expects 2025 ICL sales outside China to grow 9%-15% but ...

April 04, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and ...

A search on Google Scholar using the keywords "STAAR Surgical implantable collamer lens" yielded 1450 results. This year alone, 23 research papers have already been published on STAA's ICL.

If you have less than perfect vision seeing objects at distance, ICL is one alternative among prescription eyeglasses, removable contact lenses, and other surgical options like LASIK. STAAR ...

$5 million represents STAAR's highest quarterly ICL sales in U.S. since it obtained FDA approval for EVO ICL in March 2022. Analyst says achieving STAAR Surgical's revenue target for 2026 seems ...